N-acetylcysteine in the Prevention of Contrast-induced Acute Kidney Injury: a Systematic Review and Meta-analysis of Randomized Controlled Clinical Trials
https://doi.org/10.20996/1819-6446-2022-08-10
Abstract
Aim. To analyze the currently available published randomized controlled clinical trials to evaluate the effect of N-acetylcysteine on the incidence of contrast-induced acute kidney injury (CI-AKI).
Material and methods. The meta-analysis was performed in accordance with the PRISMA guidelines based on a search of existing literature in the PubMed/MEDLINE database for the period from 2015 to 16 February 2022. Keywords included MeSH terms «acute kidney injury» or «contrast-induced nephropathy» or «AKI» or «CIN» and «contrast media» and «N-acetylcysteine». The RoB 2 tool was used to assess study bias.
Results: When searching based on the initially selected statistics, 98 publications were identified, some of them were excluded from the analysis due to non-compliance with the inclusion criteria in this meta-analysis, 7 studies of unused sources of detection were ultimately selected, the total number of patients in the discovery was 10394.The results of the meta-analysis revealed that in patients treated with N-acetylcysteine CI-AKI developed with the same frequency as in patients who did not observe such therapy as a prophylaxis for this disease (odds ratio 1.06, 95% confidence interval 0.911.23, p=0.46).
Conclusion. The use of N-acytelcysteine does not offer any advantage in reducing the incidence of CI-AKI compared with the administration of saline solutions (sodium bicarbonate or sodium chloride 0.9%) or placebo.
About the Authors
E. M. Mezhonov
Regional clinical hospital №1; Tyumen State Medical University
Russian Federation
Russian Federation
Evgeny M. Mezhonov.
Tyumen.
eLibrary SPIN 2935-9617
Yu. A. Vyalkina
Tyumen State Medical University
Russian Federation
Russian Federation
Yulia A. Vyalkina.
Tyumen.
eLibrary SPIN 4237-5048
S. V. Shalaev
Regional clinical hospital №1; Tyumen State Medical University
Russian Federation
Russian Federation
Sergey V. Shalaev.
Tyumen.
eLibrary SPIN 5285-0082
References
1. Ehrmann S, Aronson D, Hinson JS, et al. Contrast-associated acute kidney injury is a myth: Yes. Intensive Care Med. 2018;44(1):104-6. DOI:10.1007/s00134-017-4950-6.
2. Ando G, Cortese B, Russo F et al. Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. J Am Coll Cardiol. 2017;69(21):2592-603. DOI:10.1016/j.jacc.2017.02.070.
3. Ostermann M, Zarbock A, Goldstein S, et al. Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference. JAMA Netw Open. 2020;3(10):e2019209. DOI:10.1001/jamanetworkopen.2020.19209.
4. Kaltsas E, Chalikias G, Tziakas D. The Incidence and the Prognostic Impact of Acute Kidney Injury in Acute Myocardial Infarction Patients: Current Preventive Strategies. Cardiovasc drugs Ther. 2018;32(1):81-98. DOI:10.1007/s10557-017-6766-6.
5. Kabeer MA, Cross J, Hamilton G, et al. Obesity as a Risk Factor for Radiographic Contrast-Induced Nephropathy. Angiology. 2021;72(3):274-8. DOI:10.1177/0003319720969536.
6. Ma G, Wang G, Xiao D, et al. Meta-analysis on allopurinol preventive intervention on contrast-induced acute kidney injury with random controlled trials: PRISMA. Medicine (Baltimore). 2019;98(25): e15962. DOI:10.1097/MD.0000000000015962.
7. Vandenberghe W, Hoste E. Contrast-associated acute kidney injury: does it really exist, and if so, what to do about it? F1000Res. 2019;8:753. DOI:10.12688/f1000research.16347.1.
8. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2(1):1-138. DOI:10.1038/kisup.2012.1.
9. Navarese EP, Gurbel PA, Andreotti F, et al. Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. PLoS One. 2017;12(2):e0168726. DOI:10.1371/journal.pone.0168726.
10. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. DOI:10.1136/bmj.n71.
11. Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928-d5928. DOI:10.1136/bmj.d5928.
12. Habib M, Hillis A, Hammad A. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial. Saudi J Kidney Dis Transpl. 2016;27(1):55-61. DOI:10.4103/1319-2442.174072.
13. Chong E, Poh KK, Lu Q, et al. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial. Int J Cardiol. 2015;201:237-42. DOI:10.1016/j.ijcard.2015.07.108.
14. Alrowaie F, Almatham K, Alsamadi F, et al. Could Omega 3 fatty acids reduce the risk of contrast-induced nephropathy in patients undergoing coronary angiography? A randomized controlled trial. Saudi J Kidney Dis Transplant. 2021;32(2):328. DOI:10.4103/1319-2442.335443.
15. Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. N Engl J Med. 2018;378(7):603-14. DOI:10.1056/NEJMoa1710933.
16. Garcia S, Bhatt DL, Gallagher M, et al. Strategies to Reduce Acute Kidney Injury and Improve Clinical Outcomes Following Percutaneous Coronary Intervention: A Subgroup Analysis of the PRESERVE Trial. JACC Cardiovasc Interv. 2018;11(22):2254-61. DOI:10.1016/j.jcin.2018.07.044.
17. Palli E, Makris D, Papanikolaou J, et al. The impact of N-acetylcysteine and ascorbic acid in contrast-induced nephropathy in critical care patients: An open-label randomized controlled study. Crit Care. 2017;21(1):269. DOI:10.1186/s13054-017-1862-3.
18. Usmiani T, Andreis A, Budano C,et al. AKIGUARD (Acute Kidney Injury GUARding Device) trial. J Cardiovasc Med. 2016;17(7):530-7. DOI:10.2459/JCM.0000000000000348.
Review
Supporting agencies: The study was performed with the support of the Tyumen State Medical University.
For citations:
Mezhonov E.M., Vyalkina Yu.A., Shalaev S.V. N-acetylcysteine in the Prevention of Contrast-induced Acute Kidney Injury: a Systematic Review and Meta-analysis of Randomized Controlled Clinical Trials. Rational Pharmacotherapy in Cardiology. 2022;18(4):455-461. (In Russ.) https://doi.org/10.20996/1819-6446-2022-08-10
Views: 431
Email this article 